Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Ранг среди акций #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Цена акции
$3.09
Рыночная капитализация
$58.82M
Изменение (1 день)
0.33%
Изменение (1 год)
-73.01%
Страна
US
Торговля Elicio Therapeutics, Inc. (ELTX)

Категория

Коэффициент P/B для Elicio Therapeutics, Inc. (ELTX)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Elicio Therapeutics, Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Elicio Therapeutics, Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH